Apratoxin A Reversibly Inhibits the Secretory Pathway by Preventing Cotranslational Translocation

Yanxia Liu, Brian K. Law, and Hendrik Luesch

Departments of Medicinal Chemistry (Y.L., H.L.) and Pharmacology & Therapeutics (B.K.L.), University of Florida, Gainesville, Florida

Received March 9, 2009; accepted April 29, 2009

ABSTRACT

Apratoxin A is a potent cytotoxic marine natural product that rapidly inhibits signal transducer and activator of transcription (STAT) 3 phosphorylation by an undefined mechanism. We have used biochemical and proteomics approaches to illuminate upstream molecular events. Apratoxin A inhibits Janus kinase (JAK)/STAT signaling through rapid down-regulation of interleukin 6 signal transducer (gp130). Apratoxin A also depletes cancer cells of several cancer-associated receptor tyrosine kinases by preventing their N-glycosylation, leading to their rapid proteasomal degradation. A proteomics approach revealed that several proteins in the endoplasmic reticulum, the site of N-glycoprotein synthesis, are down-regulated upon apratoxin A exposure. Using in vitro cell free systems, we demonstrated that apratoxin A prevents cotranslational translocation of proteins destined for the secretory pathway. This process is reversible in living cells. Our study indicates that apratoxins are new tools to study the secretory pathway and raises the possibility that inhibition of cotranslational translocation may be exploited for anticancer drug development.

Natural products have established a strong position as leads for drug discovery and as tools to study gene function and biological processes (Newman, 2008). For many natural products, the mechanism of action is unknown, hampering drug development and limiting their use as tool compounds in chemical biology. The exploration of marine organisms as a source of bioactive substances has been particularly prolific in recent years (Fenical and Jensen, 2006; Blunt et al., 2008). Among those, marine cyanobacteria have emerged as major producers of bioactive secondary metabolites (Gerwick et al., 2001). For example, we recently described some of the most potent natural elastase inhibitors (Taori et al., 2007) and one of the most potent class I histone deacetylase inhibitors (Taori et al., 2008; Ying et al., 2008) known, isolated from Floridian marine cyanobacteria. Whereas structure-based approaches led to their target identification, for other natural products the target is less obvious, necessitating extensive mechanistic studies on the cellular and molecular level to rationalize the biological activity. Recent examples are the apratoxins (Luesch et al., 2001, 2002; Gutiérrez et al., 2008; Matthew et al., 2008), a class of cytotoxic natural products that we (H.L.) originally isolated from a marine cyanobacterium from Micronesia (Luesch et al., 2001). The biological activity and intricate structure prompted synthetic chemists to undertake the total synthesis (Chen and Forsyth, 2004; Doi et al., 2006; Ma et al., 2006). Of the five natural apratoxins known to date, apratoxin A (Fig. 1, 1) exhibits the highest potency against various cancer cells (Luesch et al.,

This work was financially supported by the James and Esther King Biomedical Research Program, Florida Department of Health [Grant 06-NIR07] (H.L.). Initial seed funding was provided through a Junior Investigator Award (pilot grant) from the University of Florida Shands Cancer Center, American Cancer Society Institutional Research Grant [Grant ACS-IRG-01-188-01] (H.L.).

Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org. doi:10.1124/mol.109.056085.

[5] The online version of this article (available at http://molpharm.aspetjournals.org/) contains supplemental material.

ABBREVIATIONS: BIP, 70-kDa heat shock protein 5; CALR, calreticulin; c-MET, met proto-oncogene (hepatocyte growth factor receptor); DTT, dithiothreitol; ER, endoplasmic reticulum; FGFR, fibroblast growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GI50, concentration at which the cell growth is inhibited by 50%; gp130, interleukin 6 signal transducer; HER-2, ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2); HPLC, high-performance liquid chromatography; HYO1, hypoxia up-regulated 1; IGF1R-β, insulin-like growth factor 1 receptor β; IL, interleukin; iTRAQ, isobaric tag for relative and absolute quantitation; JAK, Janus kinase; LC-MS/MS, liquid chromatography-tandem mass spectrometry; MG132, N-benzoyloxy carbonyl(2)-Leu-Leu-leucinal; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; PDGFR-β, platelet-derived growth factor receptor, β polypeptide; PDI, protein disulfide isomerase; PNGase F, peptide N-glycosidase F; RPN1, ribophorin 1; RTK, receptor tyrosine kinase; siRNA, small interfering RNA; SPARC, secreted protein, acidic, cysteine-rich (osteonectin); SRP, signal recognition particle; STAT, signal transducer and activator of transcription; sulfo-NHS-SS-Biotin, sulfosuccinimidyl 2-(biotinamido)-ethyl-1,3-dithiopropionate; VEGFR, vascular endothelial growth factor receptor.
For many cancer cell lines, antiproliferative activity was found to be in the low nanomolar range (Luesch et al., 2006). We (H.L.) recently reported that apratoxin A possesses differential cytotoxicity in the NCI-60 cell line assay with a unique profile compared with standard agents (Luesch et al., 2006). Apratoxin A was shown to induce pronounced G1 cell cycle arrest and apoptosis (Luesch et al., 2006). A genomic overexpression in U2OS osteosarcoma cells revealed that ectopic induction of FGFR signaling attenuates apratoxin A activity, which was linked to the phosphorylation of oncogenic transcription factor STAT3 at its activating site, tyrosine-705 (Luesch et al., 2006). Apratoxin A potently inhibits STAT3 (Tyr705) phosphorylation in various cell types; however, the upstream events remained elusive up to now. Here we report on the mode of action of apratoxin A, including the cause for apratoxin A-induced loss of STAT3 phosphorylation. Our results indicate that apratoxin A acts via a novel mechanism.

Materials and Methods

Cell Culture

U2OS cells and MCF7 cells were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT) at 37°C humidified air and 5% CO2.

Inhibitors and Reagents

Apratoxin A was obtained from the marine cyanobacterium from Guam. The isolation of apratoxin A has been described previously (Luesch et al., 2001). MG132 and cycloheximide were purchased from Calbiochem (Gibbstown, NJ). Chloroquine, tunicamycin, and interleukin-6 (IL-6) were from Sigma-Aldrich (St. Louis, MO). Bafilomycin A1 was from BIOMOL Research Laboratories (Plymouth Meeting, PA).

Immunoblot Analysis

At a desired density (to reach ~80% confluence for control cells), U2OS cells or MCF7 cells were treated with apratoxin A (50 nM), tunicamycin (500 ng/ml), cycloheximide (1 µg/ml), or solvent controls for 1, 4, 12, and 24 h. For washout experiments, U2OS cells were seeded in 60-mm dishes at densities from 1 to 4 × 105 cells based on different time points. The next day, cells were treated with 50 nM apratoxin A or solvent control for 1, 4, 12, and 24 h. After exposure to apratoxin A, growth medium was removed, cells washed once and then cultured for additional time in apratoxin A-free medium. Whole-cell lysates were collected using PhosphoSafe lysis buffer (Novagen, Madison, WI) at 1, 4, 12, 24, 48, 72, and 96 h after begin of drug treatment. Nuclear proteins were separated using the NE-PER reagent (Pierce, Rockford, IL). Protein concentrations were measured using the BCA Protein Assay kit (Pierce). Lysates containing equal amounts of protein were separated by SDS-PAGE gel (4–12%), transferred to polyvinylidene difluoride membranes, probed with antibodies and detected with the SuperSignal West Femto Maximum Sensitivity Substrate (Pierce). Anti-gp130 antibody was obtained from Millipore (Billerica, MA). Anti-phospho-STAT3 (Tyr705), anti-STAT3, anti-phospho-JAK1 (Tyr1022/1023), anti-JAK1, anti-phospho-JAK2 (Tyr1007/1008), anti-JAK2, anti-Met (25H2), anti-VEGFR2, anti-calnexin, anti-calreticulin (CALR), anti-BIP, anti-PDI, anti-β-actin, anti-β-tubulin, anti-rabbit, and anti-mouse antibodies were from Cell Signaling Technology (Danvers, MA). Anti-Oct-1, anti-PDGF-β, anti-insulin-like growth factor 1 (Igf1) receptor, anti-FGFR2, and anti-galectin antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-HER-2 antibody was from Thermo Scientific (Waltham, MA). Anti-O-GlcNAc (monoclonal antibody carboxyl-terminal domain 110.6) and goat antimouse IgM (µ) antibodies were from Pierce. Anti-thioredoxin domain containing 5, anti-ribophorin 1 (RP1), and anti-SPARC antibodies were from Abcam (Cambridge, MA).

RNA Interference

Nontargeting control small interfering RNAs (siRNAs) and siRNA reagents targeting gp130 (sigp130) were obtained from Applied Biosystems (Foster City, CA). U2OS cells (4.0 × 105) were seeded in 60-mm dishes and transfected the next day with 10, 20, and 50 nM siRNA using siLentFect (Bio-Rad Laboratories, Hercules, CA). After 48-h incubation, whole-cell protein lysates were harvested by using PhosphoSafe lysis buffer and used for immunoblot analysis.

Quantitative Polymerase Chain Reaction after Reverse Transcription

U2OS cells (1.0 × 105) were seeded in six-well plates and transfected the next day using siLentFect (Bio-Rad Laboratories) with 1.8 µg of DNA encoding gp130 (Origene Technologies, Rockville, MD) and vector control. Cytomegalovirus-green fluorescent protein (0.2 µg) was co-transfected to monitor transfection efficiency. After 48-h incubation, total RNA was extracted with the RNeasy Mini Kit (QIAGEN, Valencia, CA). cDNA was synthesized from 2 µg of total RNA by using SuperScript II Reverse Transcriptase (Invitrogen) and Oligo(dT)12-18 Primer (Invitrogen). Real-time polymerase chain reaction was performed by using 12.5 µl of TaqMan 2× universal master mix (Applied Biosystems), 1.25 µl of 20× TaqMan gene expression assay mix (Applied Biosystems), 2 µl of cDNA, and 9.25 µl of sterile water, in a total volume of 25 µl per well reaction in 96-well plate (Applied Biosystems) using the ABI 7300 sequence detection systems (Applied Biosystems). The thermocycler program consisted of 2 min at 50°C, 10 min at 95°C, and 40 cycles of 95°C for 15 s and 60°C for 1 min. Each assay was carried out in triplicate. GAPDH expression was used as internal control for normalization.

Inhibitor Treatments

U2OS cells were seeded in 60-mm dishes (4 × 105 cells/dish). The next day, cells were pretreated with MG132 (1 µM, 30 min), chloroquine (100 µM, 30 min), or NH4Cl (20 mM, 2 h) and then exposed to apratoxin A (50 nM) or solvent control for 2, 4, and 8 h. The whole-cell protein lysates were harvested by using PhosphoSafe lysis buffer (Novagen) and used for immunoblot analysis.

LysoTracker Experiment

U2OS cells (8.0 × 105) were seeded in a 96-well plate. The next day, cells were incubated with LysoTracker Red (Invitrogen) at 37°C (final concentration, 500 nM) to label the lysosome; 30 min later, the medium was removed, the cells were washed twice with phosphate-buffered saline (PBS), and wells were refilled with culture medium. The cells were treated with apratoxin A (10 nM, 100 nM, and 1 µM) or bafilomycin A1 (5, 50, and 500 nM) or solvent controls for 3 h. The medium was removed, wells were refilled with PBS, and images were captured under a fluorescence microscope (Eclipse Ti; Nikon, Tokyo, Japan).

Chromaffin Granule (Including V-ATPase) Isolation and V-ATPase Assay

The isolation of V-ATPase containing chromaffin granules has been adapted from published procedures (Nelson et al., 1988). The V-ATPase assay was performed using an ATPase assay kit according to the manufacturer’s instructions (Innova Biosciences, Cambridge, UK).

Enzymatic Protein Deglycosylation

U2OS whole cell lysates (10 µg), 1 µl of 10× glycoprotein denaturing buffer, and water were mixed for a total volume of 10 µl. Glycoproteins were denatured by heating at 100°C for 10 min. The
enzymatic reactions were carried out in a volume of 20 μl by adding 2 μl of 10% reaction buffer, 2 μl of 10% nonidet P-40, 5 μl of water, and 1.0 μl of PNGase F (New England Biolabs, Ipswich, MA). The reaction mixture was incubated at 37°C for 1 h. Deglycosylation by PNGase F was assessed by immunoblot analysis and compared with lysates derived from U2OS cells treated with 50 nM apratoxin A, 500 ng/ml tunicamycin, or solvent control for 12 h.

**Total Protein Analysis by Silver Staining**

Silver staining was performed according to the manufacturer’s protocol (Bio-Rad Silver Stain).

**Plasma Membrane Protein Enrichment**

U2OS cells (1.8 × 10^5) were treated with apratoxin A (50 nM) or solvent control for 12 h, washed twice with PBS, and suspended in 10 mM HEPES-NaOH, pH 7.5, 0.25 M sucrose, and protease inhibitor cocktail (Pierce). The suspension was placed in a 2-ml Dounce homogenizer (Thermo Fisher Scientific, Waltham, MA), fitted with a tight (Type B) pestle and subjected to 10 to 20 down strokes of the pestle until approximately 95% of the cells were broken. The cell lysates were then centrifuged at 3000g for 10 min to remove large cell debris and nuclei. The supernatant was layered on a discontinuous sucrose density gradient containing layers of 15, 30, 45, and 60% sucrose (w/v) in 10 mM HEPES-NaOH, pH 7.5, and centrifuged at 100,000g (SW 28 rotor; Beckman Coulter, Fullerton, CA) overnight at 4°C. Resultant fractions were diluted 4-fold with distilled water and centrifuged at 200,000g (70 Ti rotor; Beckman Coulter) for 2 h to obtain plasma membrane-rich pellets, which were resuspended in PhosphaSafe lysis buffer, analyzed by SDS-PAGE, followed by silver staining or immunoblot analysis.

**N-Glycoprotein Enrichment**

U2OS cells were treated with apratoxin A (50 nM) or solvent control for 12 or 24 h. Cyttoplasmic proteins were extracted (50 mM HEPE, pH 8.0, 100 mM KOAc, 5 mM MgCl₂, 100 μg/ml digitonin, and a protease inhibitor tablet (Roche, Indianapolis, IN)) for 10 min on ice. Cells were washed (50 mM HEPE, pH 8.0, 100 mM KOAc, 5 mM MgCl₂, and protease inhibitor), membrane proteins were extracted (50 mM HEPE, pH 8.0, 100 mM KOAc, 5 mM MgCl₂, 1% Triton X-100, and protease inhibitor), the insoluble material was removed by centrifugation for 10 min at 3000g, and the supernatant was incubated with immobilized Concanavalin A agarose (Pierce) to bind cellular glycoproteins. The glycoproteins were eluted with 0.5 M triethylammonium bicarbonate and denatured with 0.1% SDS. The disulfide bonds of the proteins were reduced by 2 μl of 50 mM tris-(2-carboxyethyl)-phosphine, and the cysteine group was blocked by 1 μl of 200 mM methyl methanethiosulfonate in isopropanol. After the proteins were digested by trypsin (Promega) overnight at 37°C, the protein digest was labeled with the iTRAQ Reagents 8plex, and samples of labeled peptides from all eight different conditions were combined. The combined sample mixture was diluted into 0.1% trifluoroacetic acid, followed by loading on a MacroSpin Vydac C18 reversed-phase minicolumn (The Nest Group Inc., Southborough, MA). The eluates were dried down and dissolved in strong cation exchange solvent A (25% (v/v) acetonitrile and 10 mM ammonium formate, pH 2.8). The peptides were fractionated on an Agilent HPLC system 1100 using a polysulfoethyl A column (2.1 × 100 mm, 5 μm, 300 Å; PolyLC, Columbia, MD). Peptides were eluted at a flow rate of 200 μl/min with a linear gradient of 0 to 20% solvent B (25% (v/v) acetonitrile and 500 mM ammonium formate) over 50 min, followed by ramping up to 100% solvent B in 5 min and holding for 10 min. The absorbance at 280 nm was monitored, and a total of 14 fractions was collected. The QSTAR XL system (Applied Biosystems) was used in reversed-phase LC-MS/MS. Each strong cation exchange fraction was lyophilized and redissolved in solvent A [3% (v/v) acetonitrile (v/v) and 0.1% acetic acid (v/v)] plus 0.01% trifluoroacetic acid. The peptides were loaded onto a C18 capillary trap cartridge (LC Packings, Sunnyvale, CA) and then separated on a 15-cm nanoflow C18 column (75 μm i.d., 3 μm, 100 Å; PepMap; LC Packings) at a flow rate of 200 nM/min. Peptides were eluted from the HPLC column by a linear gradient from 3% solvent B [96.9% acetonitrile (v/v) and 0.1% acetic acid (v/v)] to 40% solvent B for 2 h, followed by ramping up to 90% solvent B in 10 min. Peptides were sprayed into the orifice of the mass spectrometer, which was operated in an information-dependent data acquisition mode in which an MS scan followed by three MS/MS scans of three highest abundance peptide ions were acquired in each cycle.

**Data Analysis.** The MS/MS data were processed by a thorough search considering biological modifications against the IPI human database (ftp://ftp.ebi.ac.uk/pub/databases/IPI/current/t/ accessed August 8, 2007) using the Paragon algorithm (Shilov et al., 2007) of ProteinPilot (ver. 2.0.1; Applied Biosystems). Fixed modification of methyl methanethiosulfonate-labeled cysteine, fixed iTRAQ modification of free amine in the N terminus and lysine, and variable iTRAQ modifications of tyrosine were considered. Parameters such as trypsin digestion, precursor mass accuracy, and fragment ion mass accuracy are built-in settings of the software. The raw peptide identification results from the Paragon Algorithm were further processed by the ProGroup algorithm. For protein relative quantification using iTRAQ, only MS/MS spectra unique to a particular protein and where the sum of the signal-to-noise ratio for all of the peak pairs greater than nine were used for quantification (software default settings, Applied Biosystems).

**Cell Viability Assay**

U2OS cells were seeded in clear-bottomed 96-well plates (5 × 10^3/well), and treated 24 h later with various concentrations of
apratoxin A (1 nM to 1 μM) or solvent control. One, 4, 12, and 24 h after treatment, culture medium was aspirated, cells were rinsed once with fresh medium, and wells were refilled with fresh medium. After a total of 48 h of incubation, cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium according to the manufacturer’s instructions (Promega). In parallel, a dose-response analysis was carried out after continuous exposure of cells to apratoxin A (48 h).

**Caspase 3/7 Assays**

U2OS cells were plated in solid-white 96-well assay plate (5 × 10³ cells/well). The same treatment and washout steps as for the cell viability assay were performed. After another 24 h of incubation, caspase 3/7 activity was measured by using Caspase-Glo 3/7 assay (Promega). Caspase-Glo 3/7 reagent was prepared immediately before use by mixing the lysis buffer and luciferase substrate and equilibrated to room temperature. The assay plate was also equilibrated to room temperature (−10 min). The same volume of Caspase-Glo 3/7 reagent as culture medium was added to each well (100 μl) and the plate was mixed on a plate shaker for ~1 min and incubated at room temperature for 30 min. The luminescence was read in a luminescence plate reader (SpectraMax M5; Molecular Devices, Sunnyvale, CA).

**In Vitro Translation**

The translation reactions containing 17.5 μl of nethyl-treated rabbit reticulocyte lysate (Promega), 0.5 μl of amino acid mix (minus methionine; 1 mM), 2.0 μl of canine pancreatic microsomal membranes (Promega), 1.0 μl of RNA substrate in nuclease-free water (β-lactamase or α-factor mRNA at 0.1 μg/μl), 1 μl of water/apratoxin A mixture (0.875 μl of water and 0.125 μl of 20 nM, 200 nM, 2 μM, 20 μM, 200 μM, and 2 mM apratoxin A or solvent control), 1.5 to 2.0 μl of L-[35S]methionine (15–20 μCi; EasyTag; PerkinElmer Life and Analytical Sciences, Waltham, MA) and nuclease-free water to a final volume of 25 μl were incubated at 30°C for 60 min. One reaction without canine pancreatic microsomal membranes was included. Five microliters of the reaction was used for analyzing the results of translation and processing by SDS-PAGE (20%) and autoradiography.

**Coupled in Vitro Transcription/Translation**

Human PDGFR-β cDNA plasmid (vector pCMV6-XL5) was obtained from Origene Technologies (Rockville, MD). In vitro transcription/translation was carried out by using Tnt T7 quick-coupled transcription/translation systems (Promega). The reactions, containing 20 μl of T7 Tnt quick master mix, 1 μl of plasmid DNA (1 μg/μl), 1.5 μl of canine pancreatic microsomal membranes (Promega), 1 μl water/apratoxin A mixture (0.875 μl of water and 0.125 μl of 20 nM, 200 nM, 2 μM, 20 μM, 200 μM, and 2 mM apratoxin A or solvent control), 1.5 to 2.0 μl of L-[35S]methionine (15–20 μCi; EasyTag), and nuclease-free water to a final volume of 25 μl were incubated at 30°C for 90 min. One reaction without canine pancreatic microsomal membranes was included. Five microliters of the reaction was used for analyzing the results of translation and processing by SDS-PAGE (7.5%) and autoradiography.

**Protease Protection Assay**

A solution of 1 mg/ml of protease K (Roche) in Tris-HCl, pH 7.5, was preincubated at 37°C for 15 min to degrade contaminating lipases. 9.5 μl of translation reactions were chilled on ice and CaCl₂ was added to 10 mM. One microliter of treated protease K was added to the translation reactions (10 μM apratoxin A and solvent control) in the presence or absence of 1% Triton X-100. The reactions were incubated at 0°C for 30 min and stopped by the addition of 2 μl of 50 mM phenylmethanesulfonyl fluoride in ethanol and immediately transferred to boiling SDS-PAGE loading buffer and then analyzed by SDS-PAGE (20%) and autoradiography.

**Results**

**Apratoxin A Inhibits Signaling through STAT3 by Depleting Cancer Cells of gp130.** The phosphorylation of STAT3 at residue Tyr-705 has been thought to be required for STAT3 translocation from the cytoplasm to the nucleus and subsequent activation of STAT3 target gene transcription (Zhong et al., 1994), although alternative mechanisms have recently been implicated (Liu et al., 2005; Yuan et al., 2005). Thus, we first tested the hypothesis that apratoxin A prevents STAT3 nuclear translocation. We prepared nuclear extracts from U2OS osteosarcoma cells treated with apratoxin A for different times and assessed STAT3 content in the nucleus by immunoblot analysis. After 4 h, STAT3 levels were significantly decreased in the nucleus, and effects were even more pronounced at later time points (Fig. 1B), supporting the proposed STAT3 inhibition. To determine whether the inhibition occurred at the level of STAT3, we turned to upstream components of signaling pathways that converge at STAT3. Because JAKs are canonical STAT3 (Tyr705) phosphorylating kinases that require phosphorylation themselves to be active, we assessed the phosphorylation status of the catalytic residues of JAK1 (Tyr1022/1023) and JAK2 (Tyr1007/1008) by immunoblot analysis with phospho-specific antibodies. Phosphorylation of both JAKs decreased over time, whereas total protein levels were unaffected (Fig. 1C). Next, we determined whether apratoxin A not only inhibited baseline STAT3 phosphorylation arising from fetal bovine serum in the growth medium but also upon cytokine activation using interleukin-6 (IL-6), a cytokine that strongly stimulates JAK-STAT3 signaling (Chen et al., 2006). Using cells that had been serum-starved for 48 h, we first established the optimal IL-6 concentration (10 ng/ml) and response time (20 min) in U2OS cells (Fig. 1D). Apratoxin A also inhibited IL-6-induced STAT3 (Tyr705) phosphorylation; however, approximately 4 h of pretreatment were required for full inhibitory effect (Fig. 1E), suggesting that another event had to occur first. Consequently, we investigated the effect of apratoxin A on interleukin 6 signal transducer (gp130), the cytokine receptor that is the shared signaling subunit of the IL-6 type cytokines (Heinrich et al., 2003). Using immunoblot analysis, we tested the protein levels of gp130 and noticed its rapid depletion in a time-dependent manner upon treatment with 50 nM apratoxin A (Fig. 1F). After 4 h, the band corresponding to gp130 in the control was already reduced by >90% compared with control, which would explain the apratoxin A-induced inhibition of STAT3 phosphorylation. Furthermore, this time course closely paralleled the effect of apratoxin A on STAT3 (Tyr705) phosphorylation, in agreement that both events are mechanistically related. To ascertain that this is the case, we obtained two independent siRNAs specifically targeting the gp130 transcript (sigp130). After verifying knockdown efficiency (>90% at 50 nM; Fig. 1G), we examined STAT3 phosphorylation status at Tyr705 and observed abrogation of Tyr705 phosphorylation in a sigp130 concentration-dependent manner while total STAT3 levels remained steady (Fig. 1G).

**Mechanism of gp130 Degradation.** To determine whether apratoxin A triggers gp130 abrogation on the transcript level, we carried out quantitative polymerase chain reaction after reverse transcription. TaqMan analysis indicated that apratoxin A had no significant effect on the
amount of gp130 mRNA within the 24 h measured (Fig. 2A). These data suggested that the down-regulation had to occur on the protein level and that apratoxin A affects protein synthesis or degradation. The two major mechanisms of protein degradation are proteasomal and lysosomal degradation. To determine the contribution of each pathway to the apratoxin A-mediated gp130 degradation, we uncoupled them by individual inhibition. First, we used the proteasome inhibitor MG132 at a previously determined effective concentration in U2OS cells [at IC50 (48 h) = 1 μM]. We pretreated U2OS cells with MG132 for 30 min before apratoxin A addition (50 nM) for 2, 4, and 8 h, then extracted cellular proteins and carried out immunoblot analysis for gp130 (Fig. 2B). Comparison of gp130 levels in MG132-pretreated cells with levels in cells that had only been treated with apratoxin A demonstrated a marginal rescue at 4 and 8 h arising from proteasome inhibition. It is noteworthy that a band of slightly lower molecular weight became apparent, suggesting that a not fully processed gp130 protein or fragment of gp130 was stabilized upon proteasome inhibitor treatment (Fig. 2B). Next, we used ammonium chloride (20 mM) to increase the pH in the lysosome to inhibit lysosomal protein degradation (Kawai et al., 2007). When cells were pretreated with NH4Cl for 2 h, the degradation of gp130 was partially inhibited or slowed (Fig. 2C), suggesting that lysosomal degradation is another fate of the fully processed and functional receptor, as previously shown (Blanchard et al., 2001). However, the immunoreactive protein of lower molecular weight was unaffected by NH4Cl. The lysosome inhibitor chloroquine (100 μM) had a similar effect but may have accelerated degradation of the faster migrating gp130 band (Fig. 2D). Rescue effects on STAT3 (Tyr705) phosphorylation were small (Fig. 2, C and D). One possible explanation for this marginal shift in activity is also that apratoxin A may trigger lysosomal degradation, which can be overcome by extending the receptor’s half-life. In the lysosome the major enzyme regulating the pH, V-ATPase, is already targeted by other anticancer drugs in development (Bowman and Bowman, 2005). Pharmacological inhibition (e.g., with the natural product bafilomycin A1) has been shown to increase the intralysosomal pH and pH of

---

**Fig. 1.** Effects of apratoxin A on STAT3 signaling in U2OS cells. A, structure of apratoxin A. B, apratoxin A promotes STAT3 nuclear translocation as determined by immunoblot analysis using U2OS nuclear extracts. Levels of the nuclear protein OCT1 did not change and cytoplasmic contamination was minimal based on probing with β-tubulin (TUBB) antibody. C, apratoxin A inhibits JAK1/JAK2 phosphorylation at the catalytic tyrosine residues as determined by immunoblot analysis using whole-cell protein extracts. Total JAK1 and JAK2 protein levels were largely unaffected. D, STAT3 (Tyr705) phosphorylation is strongly induced by IL-6 in U2OS cells. U2OS cells were first serum-starved for 48 h to reduce the level of (fetal bovine serum-mediated) constitutive STAT3 (Tyr705) phosphorylation and then stimulated with IL-6 for 20 or 60 min at various cytokine concentrations. Total proteins were isolated with PhoshoSafe lysis buffer and subjected to SDS-PAGE and Western blot analysis. Optimal conditions from this experiment leading to strongly increased STAT3 (Tyr705) phosphorylation (20 min, 10 ng/ml IL-6) were used in subsequent experiments. E, apratoxin A inhibits IL-6-induced STAT3 (Tyr705) phosphorylation in pretreated U2OS cells. Conditions from D were adopted. Serum-starved U2OS cells were pretreated with 5 or 50 nM apratoxin A for the indicated times before stimulation with IL-6, isolation of total proteins, and Western blot analysis as above. Apratoxin A prevented IL-6-mediated STAT3 (Tyr705) phosphorylation but only when cells were pretreated for 4 h or longer. Pretreatment for 1 h was not sufficient. F, apratoxin A depletes gp130 from U2OS cells concomitant with the reduction of STAT3 (Tyr705) phosphorylation as determined by immunoblot analysis. G, RNAi-mediated depletion of gp130 in U2OS cells is associated with the inhibition of STAT3 (Tyr705) phosphorylation. U2OS cells were transfected with two individual gp130-specific siRNA (or one control siRNA) mediated by siLentFect (Bio-Rad); 48 h later total proteins were extracted and SDS-PAGE-resolved proteins were analyzed by Western blotting for siRNA efficacy and effects on STAT3 phosphorylation status using anti-gp130 and anti-STAT3 (Tyr705) antibodies, respectively. STAT3 levels were unchanged. Blots in B to G are representative of at least three experiments with similar results.
other acidic V-ATPase-containing compartments, such as endosomes, interfering with autophagy (Johnson et al., 1993). Elevating endosome pH has been reported to slow receptor externalization but not internalization, and ultimately to down-regulate receptor signaling (Johnson et al., 1993). To compare the effects of apratoxin A and bafilomycin A₁, we detected acidic compartments using LysoTracker Red, which labels the lysosome red if acidic pH is not compromised. Of course, bafilomycin A₁ alkalines the lysosome by V-ATPase inhibition, so that the fluorescence disappeared (Fig. 2E). In agreement with the NH₄Cl experiment, apratoxin A does not increase the pH compared with vehicle treatment (Fig. 2E), indicating a different mode of action compared with the bafilomycins. We confirmed via enzymatic assay that apratoxin A does not affect activity of V-ATPase (purified from bovine adrenal glands), using bafilomycin A₁ as a positive control.

**Apratoxin A Down-Regulates Several Cancer-Associated Receptors.** To determine the specificity with which apratoxin A down-regulates gp130, we assessed the effects of apratoxin A on other receptors, particularly receptor tyrosine kinases (RTKs) known to be overexpressed in various cancers and that are validated targets for anticancer therapy (Baselga, 2006). Apratoxin A (50 nM) rapidly down-regulated protein levels of hepatocyte growth factor receptor (c-MET), HER-2, PDGFR-β, and insulin-like growth factor 1β receptor within several hours of treatment (Fig. 3A). Upon closer inspection of the Western blots, we consistently noticed immunoreactive bands of slightly lower molecular weight for apratoxin A-treated cells, as seen for gp130. These faster-

**Fig. 2.** Effect of apratoxin A on gp130 mRNA levels and gp130 protein degradation. A, apratoxin A has no considerable effect on gp130 transcript levels. U2OS cells were treated with apratoxin A (50 nM) and total RNA was isolated after various exposure times, reverse-transcribed to cDNA, and subjected to TaqMan analysis (n = 3). GAPDH was used as internal control for normalization. B, effect of proteasome inhibition on apratoxin A-mediated gp130 depletion. U2OS cells were pretreated with the proteasome inhibitor MG132 (1 μM) or vehicle control for 30 min before exposure to apratoxin A (50 nM) for 2, 4, or 8 h. Total proteins were isolated, resolved by SDS-PAGE, and subjected to immunoblot analysis. An immunoreactive gp130 band was increased in intensity when pretreated with MG132. The phosphorylation of STAT3 was not affected. A representative blot from three experiments with similar results is shown. C and D, effect of lysosome inhibition on apratoxin A-mediated gp130 depletion. U2OS cells were either pretreated with (C) NH₄Cl (20 mM) for 2 h or (D) chloroquine (100 μM) for 30 min, followed by treatment with apratoxin A (50 nM) for the indicated times. Total proteins were isolated, resolved by SDS-PAGE, and subjected to immunoblot analysis. Lysosome inhibition slightly attenuated the effects of apratoxin A on gp130 levels, whereas the lower immunoreactive band was not stabilized. Rescue effects with respect to STAT3 phosphorylation were marginal. Results are representative of three experiments with similar results. E, effect of apratoxin A and bafilomycin A₁ on the pH of acidic compartments (lysosome). U2OS cells were seeded in 96-well plates. The next day, cells were incubated with LysoTracker Red (Invitrogen) at 37°C (final concentration, 500 nM) to mark the acidic lysosome; 30 min later, the medium was removed, the cells were washed twice with PBS, and the wells were refilled with culture medium. The cells were treated with apratoxin A (10 nM, 100 nM, and 1 μM) or bafilomycin A₁ (5, 50, and 500 nM) or solvent controls (EtOH or dimethyl sulfoxide, respectively) for 3 h. The medium was washed out, wells were refilled with PBS, and images were captured under a fluorescence microscope (Eclipse Ti; Nikon). The red fluorescence disappeared with increasing concentration of bafilomycin A₁ as a result of alkalization, whereas apratoxin A did not affect the lysosomal pH (scale bar, 30 μm). Results are representative of three experiments with similar results.
Fig. 3. Effect of apratoxin A on receptor levels and N-linked glycosylation. A, apratoxin A down-regulates several cancer-associated receptors as determined by immunoblot analysis. U2OS cells were treated with apratoxin A for the indicated times, whole-cell lysates were prepared, and proteins were resolved by SDS-PAGE and transferred to PVDF membranes, which were then blotted with various receptor antibodies. For all receptors, a new faster migrating immunoreactive band of varying intensity consistently appeared in apratoxin A-treated samples. B, effect of the N-glycosylation inhibitor tunicamycin on various receptors and STAT3 phosphorylation compared with apratoxin A. U2OS cells were treated with tunicamycin (500 ng/ml) and subjected to immunoblot analysis as described for A. The effects of tunicamycin and apratoxin A are identical in this analysis. C, effect of the protein synthesis inhibitor cycloheximide on various receptors and STAT3 phosphorylation in comparison with apratoxin A. The same analysis as described for B was carried out for cells treated with cycloheximide (1 μg/ml). Although receptors also rapidly disappeared, cycloheximide treatment did not cause the faster migrating band to appear as tunicamycin or apratoxin A did. D, direct comparison of apratoxin A treatment and apratoxin A cotreatment with tunicamycin or cycloheximide. U2OS cells were treated with apratoxin A (50 nM) or additionally supplemented with either tunicamycin (500 ng/ml) or cycloheximide (1 μg/ml). Protein lysates from various time points were analyzed for gp130 by immunoblot analysis as described above. E, effect of apratoxin A on the degradation rate of pre-existing gp130. U2OS cells were biotinylated with Sulfo-NHS-SS-Biotin (4°C for 30 min) and then incubated with apratoxin A (50 nM) or vehicle (0.25% ethanol) for the indicated times. Protein lysates were prepared, and an aliquot was analyzed for total gp130 and STAT3 by immunoblot analysis. F, effect of apratoxin A on growth factor receptors in MCF7 cells as determined by immunoblot analysis. VEGFR2 and FGFR2 levels were strongly reduced upon 12 h of apratoxin A treatment. G, apratoxin A down-regulates several plasma membrane proteins within 12 h. U2OS cells treated with apratoxin A or control for 12 h were lysed by hypotonic treatment and cell rupture, plasma membrane proteins were isolated by sucrose density gradient ultracentrifugation as described under Materials and Methods, resolved by SDS-PAGE (4–12%) followed by immunoblot analysis (anti-PDFGR-β) to verify receptor enrichment or silver staining for total protein (lanes 3 and 4). For comparison, lanes 1 and 2 contain total cellular proteins derived from apratoxin A-treated or control cells. Effects of apratoxin A can be discerned in the plasma membrane fraction (+) but not in whole-cell lysates. H, apratoxin A reduces levels of several N-glycosylated proteins. U2OS cells were treated with apratoxin A for 12 or 24 h, and membrane proteins were isolated and enriched in N-glycoproteins by affinity capture with concanavalin A-agarose and recovered by subsequent selective elution with 0.5 M methyl-α-D-mannopyranoside. Samples were resolved by SDS-PAGE (4–12%) and subjected to immunoblot analysis (anti-gp130) to verify glycoprotein enrichment compared with whole-cell lysates (lanes 1 and 2). Another sample set was used for silver staining, revealing marked reductions in a subset of N-glycoproteins (+). Results are representative of at least three experiments with similar results.
migrating bands could be explained by the presence of the corresponding receptors with lower degree or lack of post-translational modification. Because these receptors are usually glycosylated, we suspected that the molecular weight difference could arise from deglycosylated receptors, which are more rapidly degraded (because the lack of glycosylation leads to misfolding), resulting in a less intense band. To test this hypothesis, we treated U2OS cells with tunicamycin (500 ng/ml), a broad-spectrum inhibitor of N-linked glycosylation, by inhibiting GlcNAc phosphotransferase, which catalyzes the transfer of N-acetylglucosamine-1-phosphate from UDP-N-acetylglucosamine to dolichol phosphate in the first step of glycoprotein synthesis. Tunicamycin had an identical effect on receptor levels and a time course similar to that of apratoxin A (Fig. 3B). The immunoreactive lower band corresponded to the band that was observed with apratoxin A, and in both cases this band was faint. Even tunicamycin’s effect on STAT3 (Tyr705) phosphorylation paralleled the effect of apratoxin A. This band was slightly lower than the band arising from treatment of control lysates with the endoglycosidase PNGase F (Supplementary Figure S1), which may be due to additional protein modifications in control cells but not in apratoxin A- or tunicamycin-treated cells. For comparison, the general protein synthesis inhibitor cycloheximide (1 μg/ml) decreased the levels of the receptors without inducing a second band with higher electrophoretic mobility (Fig. 3C). Apratoxin A (50 nM) cotreatment with either tunicamycin (500 ng/ml) or cycloheximide (1 μg/ml) did not accelerate gp130 down-regulation (Fig. 3D), and the lack of apparent cooperative effects at these high concentrations may suggest that apratoxin A affects only receptor synthesis and not receptor degradation. To directly demonstrate that apratoxin A does not alter the degradation rate of pre-existing receptors such as gp130, we biotinylated cell surface proteins, then treated with apratoxin A, isolated biotinylated proteins at various time points using NeutrAvidin Gel, and immunoblotted for gp130. Cell surface gp130 derived from apratoxin A-treated U2OS cells disappeared at the same rate as cell surface gp130 from vehicle-treated cells (Fig. 3E).

Because we were unable to detect significant protein levels of FGFRs and VEGFR2, and to assess cell type specificity, we determined whether apratoxin A can reduce expression levels of these cancer-associated receptors linked also to angiogenesis in the MCF7 breast cancer cell line (Garvin et al., 2005). Apratoxin A (50 nM) strongly down-regulated FGFR2 and VEGFR2 in this cell line after 12 h of exposure (Fig. 3F). We subsequently isolated the plasma membrane fraction from apratoxin A-treated (12 h) and control U2OS cells by ultracentrifugation over sucrose gradients to compare total cell surface protein content. We verified receptor enrichment using PDGFR-β immunoblot analysis (Fig. 3G). Although we were unable to identify discernible differences in treated versus untreated whole-cell lysates by silver staining (Fig. 3G, lanes 1 versus 2), several but not all plasma membrane protein levels were reduced upon apratoxin A treatment (Fig. 3G, lanes 3 versus 4, *), suggesting a selective effect of apratoxin A on a subset of glycosylated cell surface proteins. To test whether the effect of apratoxin A is specific to N-glycosylation, we resolved protein lysates by SDS-PAGE and carried out Western blot analysis for O-glycosylation using O-GlcNAc antibody. No significant differences were apparent between control lysates and those derived from cells treated with apratoxin A for 1, 4, 12, or 24 h (not shown). Conversely, lysates collected after various treatment times that were then enriched in glycoproteins through lectin-based isolation using concanavalin A agarose, validated by gp130 immunoblot analysis (Fig. 3H), showed differences after 12 h and more pronounced after 24 h of apratoxin A treatment (Fig. 3H, *). It is noteworthy that this analysis also identified changes in the 50-kDa range, which presumably are not receptors (Fig. 3H). These results overall suggested that 1) apratoxin A action is specific to N-linked glycosylation and 2) only a subset of proteins is affected.

Proteomics Identifies Subcellular Consequences of Apratoxin A Treatment. To ascertain which other protein levels may be modulated by apratoxin A, we employed an iTRAQ-based proteomics approach that allows multiplexed relative protein quantification in a single LC-MS/MS experiment (Aggarwal et al., 2006). We compared protein lysates from cells treated with apratoxin A versus vehicle for 1, 4, 12, and 24 h, initially focusing on whole-cell lysates. Proteins were extracted and precipitated and digested with trypsin, and the resulting peptide mixtures for different conditions were individually labeled with 8-plex isobaric iTRAQ reagents and then combined to one single sample, fractionated over cation exchange resin, and subjected to LC-MS/MS analysis (Fig. 4A, middle). As with the silver staining of SDS-PAGE resolved whole-cell lysates, this experiment failed to disclose significant differences or reproducible trends. However, because we revealed major effects on several receptors (Fig. 3A), our strategy was to specifically label cell surface proteins with biotin through coupling with Sulfo-NHS-SS-Biotin (Fig. 4A, 2) (4°C, 30 min) after apratoxin A treatment and then to use NeutrAvidin Gel to isolate biotin-labeled and -associated proteins. Tagged proteins were then eluted by DTT-mediated reductive disulfide cleavage of the biotin-containing reagent, leaving a cap behind. Downstream analysis would allow direct comparison of protein levels (Fig. 4A, right). We verified labeling by blotting with horseradish peroxidase-conjugated streptavidin (Fig. 4B), subsequently enriched biotinylated proteins using NeutrAvidin-agarose beads, reductively cleaved the biotin tag during elution, and confirmed that receptors such as gp130 have been enriched by this procedure (Fig. 4C). Silver staining of SDS-PAGE gels for total protein content further showed that we enriched a minor subset of proteins. The same analysis also confirmed that there are no apparent differences between whole-cell lysates treated with vehicle or apratoxin A, and it revealed only minor differences for lysates collected after biotin-labeling of apratoxin A and vehicle-treated cells when equal amounts of protein were loaded onto the gel (Fig. 4C). Taken together, these data show that apratoxin A affected only a fairly specific subset of proteins. It is noteworthy that approximately 4 to 6% of the original protein content was recovered each time, suggesting that proteins presumably associated with cell-surface proteins were also enriched or that labeling was not entirely specific. We proceeded with the iTRAQ labeling and downstream analysis as described above (Fig. 4A, right). Peptides were identified by LC-MS/MS analysis, and numerous time-dependent changes were observed. At a confidence level of 95% with at least one peptide hit at each of the time points, we identified 476 proteins, 66 of which showed at least a 2-fold change at one of the four time points.
Most of the proteins of lower expression in the apratoxin A-treated samples could easily be classified into receptor- or membrane-associated proteins, protein disulfide isomerase (PDI) related proteins (which can serve or interact with chaperones), and other proteins that mainly reside in the endoplasmic reticulum (ER) (Table 1; see Supplementary Table).

**Fig. 4.** Proteomics reveals additional effects of apratoxin A on receptors and the ER. A, method for iTRAQ-based quantification of whole-cell proteome or cell surface protein-enriched proteomics. U2OS cells were treated with apratoxin A or vehicle control for 1, 4, 12, or 24 h. Either total proteins were extracted (middle) or cells were biotinylated with Sulfo-NHS-SS-Biotin (2) at 4°C for 30 min and lysed, and biotinylated proteins were enriched by NeutrAvidin-agarose binding and subsequent DTT-mediated disulfide cleavage (right). In both scenarios, proteins are precipitated, digested, and labeled with 8-plex isobaric iTRAQ reagents according to the manufacturer’s protocol (Applied Biosystems). The eight labeled digests from each approach were combined, fractionated by cation exchange, and analyzed by reversed-phase (C18) HPLC-MS/MS. Peptides and parent proteins were identified and quantified based on iTRAQ labels by ProteinPilot analysis. Subsequent validation is described in D. Each proteomic analysis was carried out one time. B and C, validation of biotinylation. Lysates from biotinylated cells were separated by SDS-PAGE (4–12%) and subjected to Western blot analysis (B) before NeutrAvidin-agarose incubation, probing for biotin with streptavidin-horseradish peroxidase, which indicated high levels of biotinylation in the mid to high molecular weight range, and (C) after DTT-mediated elution from NeutrAvidin, probing for gp130 levels, which indicated a strong enrichment. C also shows a silver-stained SDS-PAGE gel revealing some minor differences between apratoxin A and control samples (+). For comparison, whole-cell lysate analysis is included in the left lanes (lanes 1 and 2). Immunoblot (B) and silver staining (C) analyses are representative of two and three experiments, respectively. D, validation of proteomics results: apratoxin A reduces levels of several ER proteins. U2OS cells were treated with apratoxin A or control for 1, 4, 12, or 24 h, whole-cell lysates were collected, and total cellular proteins were resolved by SDS-PAGE and subjected to immunoblot analysis for various ER proteins from Table 1. As a control, apratoxin A did not change SPARC levels. E, tunicamycin’s effects on components of the ER are different from the effect of apratoxin A. A similar analysis as in D, using U2OS cells treated with tunicamycin (500 ng/mL) and probing for ER proteins that are reduced upon apratoxin A treatment (CALR, BIP, RPNI), indicated that CALR levels are unaffected by tunicamycin and BIP levels strongly increased, whereas RPNI levels are decreased as for apratoxin A. Blots in D and E are representative of three experiments with similar results.
Selected apratoxin A (50 nM) induced -fold changes in levels of proteins enriched after cell surface biotinylation of U2OS cells (quantified by LC-MS/MS).

**TABLE 1**

Selected apratoxin A (50 nM) induced -fold changes in levels of proteins enriched after cell surface biotinylation of U2OS cells (quantified by iTRAQ labeling) (95% confidence level)

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Annotation</th>
<th>Peptides*</th>
<th>1 h</th>
<th>4 h</th>
<th>12 h</th>
<th>24 h</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Receptors/cell surface proteins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LRPAP1</td>
<td>Low-density lipoprotein receptor-related protein</td>
<td>8</td>
<td>-1.13</td>
<td>-1.61</td>
<td>-4.06</td>
<td>-3.79</td>
</tr>
<tr>
<td>M6PR</td>
<td>Mannose-6-phosphate receptor (cation dependent)</td>
<td>4</td>
<td>+1.02</td>
<td>+1.07</td>
<td>-2.70</td>
<td>-1.54</td>
</tr>
<tr>
<td>CD151</td>
<td>CD151 molecule (Ralph blood group)</td>
<td>1</td>
<td>-1.01</td>
<td>+1.02</td>
<td>-2.63</td>
<td>-1.37</td>
</tr>
<tr>
<td>GPC1</td>
<td>Glycican 1</td>
<td>7</td>
<td>+1.36</td>
<td>+1.02</td>
<td>-2.21</td>
<td>-1.65</td>
</tr>
<tr>
<td>ITGA7</td>
<td>Integrin, αβ (vitronectin receptor, α polypeptide)</td>
<td>21</td>
<td>+1.15</td>
<td>-1.03</td>
<td>-2.04</td>
<td>-1.76</td>
</tr>
<tr>
<td>TFRC</td>
<td>Transferrin receptor (p90, CD71)</td>
<td>28</td>
<td>+1.01</td>
<td>-1.25</td>
<td>-1.83</td>
<td>-2.79</td>
</tr>
<tr>
<td>DAG1</td>
<td>Dystroglycan 1 (dystrophin-associated glycoprotein 1)</td>
<td>13</td>
<td>-1.09</td>
<td>-1.25</td>
<td>-1.71</td>
<td>-2.26</td>
</tr>
<tr>
<td>ITGB1</td>
<td>Integrin, β1 (fibronectin receptor, β polypeptide)</td>
<td>20</td>
<td>-1.06</td>
<td>-1.06</td>
<td>-1.56</td>
<td>-1.98</td>
</tr>
<tr>
<td>CDDC47</td>
<td>Coiled-coil domain containing 47</td>
<td>4</td>
<td>+1.07</td>
<td>+1.38</td>
<td>-1.35</td>
<td>-13.87</td>
</tr>
<tr>
<td>ANXA1</td>
<td>Annexin A1</td>
<td>5</td>
<td>+1.61</td>
<td>-1.12</td>
<td>+2.01</td>
<td>+1.81</td>
</tr>
<tr>
<td><strong>Protein disulfide isomerases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDI A3</td>
<td>Protein disulfide isomerase family A member 3</td>
<td>23</td>
<td>+1.10</td>
<td>+1.15</td>
<td>-1.65</td>
<td>-3.02</td>
</tr>
<tr>
<td>PDI A4</td>
<td>Protein disulfide isomerase family A member 4</td>
<td>17</td>
<td>-1.04</td>
<td>+1.17</td>
<td>-1.93</td>
<td>-4.15</td>
</tr>
<tr>
<td>PDI A6</td>
<td>Protein disulfide isomerase family A member 6</td>
<td>12</td>
<td>-1.15</td>
<td>-1.04</td>
<td>-1.71</td>
<td>-2.86</td>
</tr>
<tr>
<td>TXNDC4</td>
<td>Thioredoxin domain containing 4 (endoplasmic reticulum)</td>
<td>7</td>
<td>+1.10</td>
<td>-1.13</td>
<td>-1.78</td>
<td>-2.14</td>
</tr>
<tr>
<td><strong>TXNDC5</strong></td>
<td>Thioredoxin domain containing 5</td>
<td>8</td>
<td>+1.13</td>
<td>+1.31</td>
<td>-1.88</td>
<td>-3.20</td>
</tr>
<tr>
<td><strong>Other ER proteins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CALU</td>
<td>Calumenin</td>
<td>8</td>
<td>-1.19</td>
<td>+1.11</td>
<td>-2.52</td>
<td>-5.08</td>
</tr>
<tr>
<td>RCN1</td>
<td>Reticulocalbin 1, EF-hand calcium binding domain</td>
<td>8</td>
<td>-1.08</td>
<td>+1.04</td>
<td>-2.39</td>
<td>-5.87</td>
</tr>
<tr>
<td>RCN2</td>
<td>Reticulocalbin 2, EF-hand calcium binding domain</td>
<td>5</td>
<td>-1.14</td>
<td>-1.15</td>
<td>-2.13</td>
<td>-2.14</td>
</tr>
<tr>
<td>HSPA5</td>
<td>70-kD heat shock protein 5 (glucose-regulated protein, 78 kDa)</td>
<td>28</td>
<td>-1.02</td>
<td>+1.08</td>
<td>-2.08</td>
<td>-3.70</td>
</tr>
<tr>
<td>LMAN1</td>
<td>Lectin, mannos-binding, 1</td>
<td>11</td>
<td>-1.09</td>
<td>-1.13</td>
<td>-2.03</td>
<td>-2.67</td>
</tr>
<tr>
<td>HYOU1</td>
<td>Hypoxia up-regulated 1</td>
<td>27</td>
<td>-1.14</td>
<td>+1.24</td>
<td>-2.02</td>
<td>-3.02</td>
</tr>
<tr>
<td>CANX</td>
<td>Calnexin</td>
<td>14</td>
<td>-1.08</td>
<td>-1.12</td>
<td>-2.02</td>
<td>-3.21</td>
</tr>
<tr>
<td>HPSP90B1</td>
<td>90-kD heat shock protein β (Grp94), member 1</td>
<td>38</td>
<td>±1.00</td>
<td>+1.15</td>
<td>-1.95</td>
<td>-3.11</td>
</tr>
<tr>
<td>STTS8</td>
<td>STTS, subunit of the oligosaccharyltransferase complex, Homolog A (S. cerevisiae)</td>
<td>8</td>
<td>+1.31</td>
<td>-1.11</td>
<td>-1.90</td>
<td>-1.99</td>
</tr>
<tr>
<td>RPNI</td>
<td>Ribophorin I</td>
<td>13</td>
<td>-1.06</td>
<td>-1.13</td>
<td>-1.77</td>
<td>-2.23</td>
</tr>
<tr>
<td>PPBP</td>
<td>Peptidylprolyl isomerase B (cyclophilin B)</td>
<td>14</td>
<td>-1.05</td>
<td>+1.36</td>
<td>-1.75</td>
<td>-3.32</td>
</tr>
<tr>
<td>CALR</td>
<td>Calreticulin</td>
<td>12</td>
<td>-1.15</td>
<td>+0.82</td>
<td>-1.69</td>
<td>-3.46</td>
</tr>
<tr>
<td>GABA</td>
<td>Glutamic acid, alpha; neutral AB</td>
<td>27</td>
<td>-1.06</td>
<td>+1.24</td>
<td>-1.64</td>
<td>-3.12</td>
</tr>
<tr>
<td>UCCGL1</td>
<td>UDP-glucose ceramide glucosyltransferase-like 1</td>
<td>17</td>
<td>-1.28</td>
<td>-1.08</td>
<td>-1.06</td>
<td>-2.77</td>
</tr>
<tr>
<td><strong>tRNA synthetases &amp; protein biosynthesis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RARS</td>
<td>Arginyl-tRNA synthetase</td>
<td>13</td>
<td>+1.04</td>
<td>-1.02</td>
<td>+1.43</td>
<td>+2.21</td>
</tr>
<tr>
<td>QARS</td>
<td>Glutamyl-tRNA synthetase</td>
<td>15</td>
<td>-1.20</td>
<td>-1.15</td>
<td>+1.44</td>
<td>+1.47</td>
</tr>
<tr>
<td>DARS</td>
<td>Aspartyl-tRNA synthetase</td>
<td>9</td>
<td>-1.06</td>
<td>-1.15</td>
<td>+1.56</td>
<td>+1.85</td>
</tr>
<tr>
<td>KARS</td>
<td>Lysyl-tRNA synthetase</td>
<td>15</td>
<td>+1.06</td>
<td>+1.07</td>
<td>+1.59</td>
<td>+1.41</td>
</tr>
<tr>
<td>TARS</td>
<td>Threonyl-tRNA synthetase</td>
<td>11</td>
<td>-1.35</td>
<td>+1.13</td>
<td>+1.86</td>
<td>+1.29</td>
</tr>
<tr>
<td>IARS</td>
<td>Isoleucyl-tRNA synthetase</td>
<td>21</td>
<td>+1.63</td>
<td>-1.04</td>
<td>+2.02</td>
<td>+1.69</td>
</tr>
<tr>
<td>RPL12</td>
<td>Ribosomal protein L12</td>
<td>3</td>
<td>+1.27</td>
<td>+1.86</td>
<td>+2.32</td>
<td>+2.15</td>
</tr>
<tr>
<td>EIF3D</td>
<td>Eukaryotic translation initiation factor 3, subunit D</td>
<td>3</td>
<td>-1.61</td>
<td>-1.43</td>
<td>+2.39</td>
<td>+1.11</td>
</tr>
<tr>
<td>SRP72</td>
<td>Signal recognition particle 72 kDa</td>
<td>12</td>
<td>-1.32</td>
<td>-1.08</td>
<td>+2.55</td>
<td>+1.50</td>
</tr>
</tbody>
</table>

* Used for protein identification.
site of glycoprotein synthesis. We then directly compared the regulation of selected validated proteins with the effect of tunicamycin on U2OS cells (Fig. 4E). Like apratoxin A, tunicamycin induced the down-regulation of RPN1. However, unlike the response to apratoxin A, CALR levels seemed slightly elevated after 24 h of tunicamycin treatment, and BIP was strongly induced (Fig. 4E), consistent with the induction of the unfolded protein response (Gulow et al., 2002). This response is opposite that of apratoxin A treatment (Fig. 4D). These data indicated that the targets of both compounds are different, although their mechanisms of action converge downstream.

**Apratoxin A Inhibits Cotranslational Processing in Vitro.** The down-regulation of receptors and other proteins associated with the secretory pathway could be explained by inhibition of protein synthesis or by inhibition of processing, including post-translational modification. In the latter case, unprocessed or nonglycosylated proteins may quickly be degraded by the proteasome because of misfolding. The experiments in cell culture in which a proteasome inhibitor increased the intensity of nonglycosylated receptor suggested that this may be the case. To test this hypothesis and distinguish whether apratoxin A inhibits the synthesis of down-regulated proteins or only downstream processing events, we turned to in vitro translation with or without microsomal membrane and incorporating \[^{35}S\]methionine, followed by SDS-PAGE and autoradiography. Using \(\alpha\)-factor mRNA as a standard substrate to assess effects on glycosylation, we determined that apratoxin A does not inhibit protein synthesis; however, glycosylation is inhibited even in the presence of microsomal membranes, as evidenced by the lack of the higher bands representing glycosylated forms (Fig. 5A) (Hansen et al., 1986). The inhibition of \(\alpha\)-factor glycosylation occurs in a dose-dependent manner, the IC\(_{50}\) being in the 100-nM range (Fig. 5B). To determine whether apratoxin A also inhibits signal peptide cleavage, the event that precedes post-translational modifications such as N-glycosylation, we used mRNA of \(\beta\)-lactamase as a substrate because the signal peptide-cleaved (processed) protein can be readily distinguished from the unprocessed form based on their migration by SDS-PAGE. As shown in Fig. 5C, apratoxin A fully inhibits the cleavage of the signal peptide; no lower band for the

---

**Fig. 5.** Apratoxin A inhibits cotranslational translocation in vitro. For in vitro translation reactions (A–E), rabbit reticulocyte lysate, amino acid mix (minus methionine), \[^{35}S\]methionine, and mRNA substrate were incubated in the presence or absence of canine pancreatic microsomal membranes with apratoxin A or solvent control. Samples were resolved by SDS-PAGE (20% for A–E and 7.5% for F), and proteins were transferred to nitrocellulose membranes and detected by autoradiography. A and B, effect of apratoxin A on in vitro translation and glycosylation of \(\alpha\)-factor mRNA. In the absence of microsomal membranes (A, left lanes, 1 and 2), \(\alpha\)-factor is synthesized regardless of the presence of apratoxin A (10 \(\mu\)M). In the presence of microsomal membranes (A, right lanes, 3 and 4), apratoxin A (10 \(\mu\)M) inhibits the glycosylation of \(\alpha\)-factor. This inhibition occurs in a dose-dependent fashion (B) with an approximate IC\(_{50}\) of 100 nM. C and D, effect of apratoxin A on in vitro translation of \(\beta\)-lactamase mRNA and subsequent signal peptide cleavage (processing). Although apratoxin A does not interfere with the synthesis of \(\beta\)-lactamase (C, no membrane, left lanes, 1 and 2), it inhibits the cleavage of the signal peptide (C, lane 4), which is usually observed after incubation with microsomal membranes (C, lane 3). D, this inhibition is dose-dependent (IC\(_{50}\) between 100 nM and 1 \(\mu\)M). E, protease protection: apratoxin A diverts protein synthesis to the cytoplasm. Proteinase K readily digests nonglycosylated (precursor) \(\alpha\)-factor (lane 2) but glycosylated proteins only in the presence of detergent (Triton X-100, lane 3). In the presence of apratoxin A, \(\alpha\)-factor is degraded and thus not effectively inserted into the membrane. F, apratoxin A inhibits glycosylation of a mammalian receptor in vitro. In vitro transcription/translation was carried out using the T7 TnT Quick Master Mix, PDGFR-\(\beta\) plasmid cDNA, canine microsomal membranes, \[^{35}S\]methionine, and apratoxin A or solvent control. Subsequently, samples were resolved by SDS-PAGE, and proteins were transferred to nitrocellulose membranes and detected by autoradiography. Apratoxin A does not affect the synthesis of PDGFR-\(\beta\), but it prevents its glycosylation in a dose-response manner (IC\(_{50}\) ~ 100 nM). Results are representative of at least two experiments with similar results.
processed form appears even in the presence of microsomal membranes. This inhibition also occurred in a dose-dependent fashion (Fig. 5D). Subsequent treatment of the α-factor translation reactions with proteinase K (Hansen et al., 1986) revealed that the synthesized protein is unprotected from protease and thus synthesis is diverted to the cytoplasm (Fig. 5E), in agreement with the proteasome inhibitor data presented above. In contrast (and as a control experiment), proteinase K had no effect on the glycosylated receptor because it was protected as a result of envelopment by the membrane. However, in the presence of detergent (1% Triton X-100), the membrane became permeable and proteinase K digested the fully processed receptor as well. We then showed by coupled in vitro transcription/translation, using a more relevant mammalian cDNA template, that the glycosylation of a human receptor, PDGFR-β, is also inhibited in vitro in a similar fashion (Fig. 5F).

Apratoxin A-Induced Loss of Receptors and Antiproliferative Activity Is Reversible. To investigate the reversibility of apratoxin A-induced antiproliferative activity and ascertain when cells commit to apoptosis, we tested whether removal of medium several hours after apratoxin A treatment would affect its cell growth inhibitory activity and cytotoxicity (measured after 48 h). Clearly, the dose-response curve shifted toward higher GI50 and IC50 values when apratoxin A-treated U2OS cells are washed within 24 h (Fig. 6A). Washout within the first 24 h could largely prevent cytotoxicity and lead to only a transitory reduction in cell growth. Washout also prevented the induction of apoptosis as measured using Caspase-Glo 3/7 at concentrations of up to 100 to 102 Liu et al.

![Diagram](image.png)

**Fig. 6.** The effects of apratoxin A are reversible. U2OS cells were treated with various concentrations of apratoxin A for 1, 4, 12, and 24 h, the medium was removed, and cells were washed once and replenished with fresh medium. A, removal of apratoxin A within several hours of treatment attenuates its effect on cell viability. Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium assay 48 h after the beginning of apratoxin A treatment. For comparison, a dose-response analysis was included in parallel. IC50 and GI50 values are 8- to 30-fold higher if medium containing apratoxin A is replaced with fresh medium within 1 to 24 h. When cells were washed at any of the time points, there was only marginal cytotoxicity observed at higher concentrations. Experiments were carried out in triplicate. Values are presented as mean ± S.D. B, removal of apratoxin A within several hours of treatment prevents apoptosis. Caspase 3/7 activity was measured using the Caspase-Glo 3/7 kit (Promega) 48 h after initial exposure to apratoxin A. For comparison, a dose-response analysis was included in which cells have been continuously exposed to apratoxin A for 48 h. Dose-response curves are shifted by ~30-fold, and residual caspase 3/7 activity may be attributed to incomplete removal of apratoxin A-containing medium. Error bars indicate standard deviations from mean of three independent experiments. C, the effects of apratoxin A on receptor levels are reversible. After apratoxin A washout, cells were further incubated with fresh medium, and total proteins were collected using PhosphoSafe lysis buffer 1, 4, 12, 24, 48, 72, or 96 h after the beginning of apratoxin A treatment. Proteins were resolved by SDS-PAGE and subjected to Western blot analysis. Receptor levels (gp130, PDGFR-β) recovered, and at later time points, the phosphorylation of STAT3 was partially or completely restored. Blots are representative of at least two experiments with similar results.
However, there is precedence for an anti-inflammatory fun-
gal cyclodepsipeptide HUN-7293, minor variations of which
known as cotransin and CAM741 act by a similar mechanism
(Besemer et al., 2005; Garrison et al., 2005). Cotransin and
CAM741 have a selectivity profile that is different from apra-
toxin A and mainly down-regulate vascular cell adhesion
molecule 1 (Besemer et al., 2005; Garrison et al., 2005). Using
photoaffinity labeling, cotransin’s target was recently shown
to be Sec61α (MacKinnon et al., 2007), an essential compo-
nent of the translocon, which is sealed on the luminal end by
BIP (down-regulated by apratoxin A; Fig. 4D) before and
early in translocation (Hamman et al., 1998). The Sec61-
-containing translocon complex, particularly Sec61α, is one
candidate target for apratoxins. Interfering with the SRP,
which could prevent SRP-induced elongation arrest, could
also explain the observations. However, the effect of apra-
toxin A on the function of the ER—even though much later
than when translocation and processing are inhibited (Table
1 and Fig. 4D)—may be suggestive of an ER component of the
translocation machinery as the apratoxin A target. Upstream
alternatives are the SRP complex, SRP receptor, or signal
sequence, because the cDNA sequences for at least several of
the ER proteins (e.g., HYOU1, calnexin, CALR) that are
down-regulated by apratoxin A predict an N-terminal signal
sequence and rely on the signal recognition machinery. The
protection assay (Fig. 5E) suggests that signal peptidase is
not the target of apratoxin A; otherwise, membrane targeting
and translocation would have been unaffected. The unambig-
uous target identification will probably require affinity-based
methods that are currently being pursued in our laboratory.

In summary, we have shown that apratoxin A reversibly
inhibits the secretory pathway for several cancer-associated
receptors by interfering with cotranslational translocation.
Apratoxin A shows nanomolar activity in cancer cells and in
cell-free systems. Modulating the secretory pathway with
apraotxin-based small molecules represents a new reversible
method in live cells that may become a valuable new tool for
investigating the secretory pathway. Apratoxin A selectivity
needs to be further established and may be modulated
through ongoing structure-activity relationship studies. This
approach may have value for a variety of disease states in
which production of secretory or membrane proteins is in-
volved, and their down-regulation would be beneficial.

Acknowledgments
We thank S. McClung and S. Chen for supporting the proteomics
work and T. Rowe, M. Law, N. Parker, P. Corsino, and B. Davis for
technical assistance.

References
Aggarwal K, Choe LH, and Lee KH (2006) Shotgun proteomics using the iTRAQ
312:1175–1178.
of cotranslational translocation of vascular cell adhesion molecule 1. Nature
436:293–293.
Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory
factor receptor α, and oncostatin M receptor β by distinct mechanisms. J Biol
Chen J and Forsyth CJ (2004) Total synthesis of the marine cyanobacterial cyclodep-
suppresses IL-6-induced STAT3 activation and gene expression in endothelial cells. \textit{Br J Pharmacol} \textbf{148}:238–232.


\textbf{Address correspondence to:} Hendrik Luesch, Department of Medicinal Chemistry, University of Florida, 1600 SW Archer Road, PO Box 100485, Gainesville, Florida 32610. E-mail: luesch@cop.ufl.edu